ライフサイエンスコーパス: cholangiopancreatography

1 er endoscopies, and 58 endoscopic retrograde cholangiopancreatographies).

2 iliary stent placed by endoscopic retrograde cholangiopancreatography.

3 ning biliary access at endoscopic retrograde cholangiopancreatography.

4 -Science Conference on endoscopic retrograde cholangiopancreatography.

5 tis in comparison with endoscopic retrograde cholangiopancreatography.

6 uces the incidence of pancreatitis following cholangiopancreatography.

7 iatric experience with endoscopic retrograde cholangiopancreatography.

8 hose at helical CT and endoscopic retrograde cholangiopancreatography.

9 cells obtained during endoscopic retrograde cholangiopancreatography.

10 pcSEMS (n = 71) during endoscopic retrograde cholangiopancreatography.

11 oth endosonography and endoscopic retrograde cholangiopancreatography.

12 cture was confirmed by endoscopic retrograde cholangiopancreatography.

13 The first description of magnetic resonance cholangiopancreatography, a new noninvasive imaging stud

14 hemoprevention of post-endoscopic retrograde cholangiopancreatography acute pancreatitis and enteral

15 hemoprevention of post-endoscopic retrograde cholangiopancreatography acute pancreatitis remains unpr

16 ET/CT, MDCT, and MR imaging combined with MR cholangiopancreatography, all of which were evaluated in

17 Specificities for MR cholangiopancreatography alone and for MR cholangiopancr

18 yields higher diagnostic performance than MR cholangiopancreatography alone.

19 ct cholangiography (45 endoscopic retrograde cholangiopancreatography and 1 percutaneous transhepatic

20 tomy was defined using endoscopic retrograde cholangiopancreatography and categorized as a normal duc

21 Magnetic resonance cholangiopancreatography and endoscopic ultrasound are d

22 Timing of endoscopic retrograde cholangiopancreatography and outcome were stratified by

23 The combination of T2-weighted MR cholangiopancreatography and T1-weighted imaging yields

24 on with the results of endoscopic retrograde cholangiopancreatography and the secretin test.

25 hy, contrast material-enhanced MR imaging/MR cholangiopancreatography, and ASGE risk stratification g

26 ography scan, ultrasound, magnetic resonance cholangiopancreatography, and direct cholangiography.

27 ical computed tomography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography

28 opic retrograde cholangiopancreatography, MR cholangiopancreatography, and fluoroscopy will be demons

29 , computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging

30 for pancreatitis after endoscopic retrograde cholangiopancreatography, and refinements in photodynami

31 gnetic resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound.

32 ic ultrasonography and endoscopic retrograde cholangiopancreatography are just beginning to be assess

33 ng therapeutic role of endoscopic retrograde cholangiopancreatography as well as improvements in our

34 gations in therapeutic endoscopic retrograde cholangiopancreatography as well as knowledge gaps for f

35 of pancreatitis after endoscopic retrograde cholangiopancreatography as well as morbidity in the eld

36 undergoing therapeutic endoscopic retrograde cholangiopancreatography at university hospitals in Euro

37 on guidelines versus magnetic resonance (MR) cholangiopancreatography-based treatment of patients wit

38 Endoscopic retrograde cholangiopancreatography brushings were obtained from 49

39 that balloon-assisted endoscopic retrograde cholangiopancreatography can achieve papillary cannulati

40 MR cholangiopancreatography can depict congenital and acqui

41 iven immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acu

42 any cases, therapeutic endoscopic retrograde cholangiopancreatography can take the place of invasive

43 uted tomography scans, endoscopic retrograde cholangiopancreatography, carcinoembryonic antigen, and

44 Endoscopic retrograde cholangiopancreatography confirmed the diagnosis and all

45 Pediatric endoscopic retrograde cholangiopancreatography continues to evolve, with incre

46 possible choledocholithiasis: noncontrast MR cholangiopancreatography, contrast material-enhanced MR

47 Sensitivities for T2-weighted MR cholangiopancreatography data alone were 0.65, 0.70, and

48 Timing of endoscopic retrograde cholangiopancreatography does not appear to affect clini

49 Magnetic resonance cholangiopancreatography enables reliable diagnosis of c

50 software manipulation of magnetic resonance cholangiopancreatography, enabling preoperative VR explo

51 ctor computed tomography, magnetic resonance cholangiopancreatography, endoscopic ultrasonography, an

52 holecystectomies and 4 endoscopic retrograde cholangiopancreatography/endoscopic sphincterotomies (ER

53 ts undergoing elective endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasono

54 eviewed the results of endoscopic retrograde cholangiopancreatography (ERCP) and intraoperative chola

55 increased by previous endoscopic retrograde cholangiopancreatography (ERCP) and stent placement, and

56 e scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) between March 26, 2008,

57 MRCP obviated endoscopic retrograde cholangiopancreatography (ERCP) by excluding choledochol

58 biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) can result in failure of

59 contrast agents during endoscopic retrograde cholangiopancreatography (ERCP) causes pancreatic inflam

60 nostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) continues to mature.

61 sy and others, such as endoscopic retrograde cholangiopancreatography (ERCP) cytology, are problemati

62 logy/surgical findings/Endoscopic Retrograde CholangioPancreatography (ERCP) findings as applicable.

63 aphy (EUS) may replace endoscopic retrograde cholangiopancreatography (ERCP) for the detection of CBD

64 mples were obtained at endoscopic retrograde cholangiopancreatography (ERCP) in 59 patients with gall

65 opy allows therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in these patients, avoid

66 Endoscopic retrograde cholangiopancreatography (ERCP) is a technically challen

67 Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demandi

68 rmed endoscopically by endoscopic retrograde cholangiopancreatography (ERCP) or by percutaneous trans

69 evaluated by means of endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance ch

70 the prevention of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.

71 d duodenoscopes during endoscopic retrograde cholangiopancreatography (ERCP) procedures.

72 h PSC established with endoscopic retrograde cholangiopancreatography (ERCP) were compared with the M

73 agement often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphin

74 Endoscopic retrograde cholangiopancreatography (ERCP) with or without sphincte

75 cholithiasis requiring endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction re

76 phy (US), 21 patients; endoscopic retrograde cholangiopancreatography (ERCP), 19 patients; and percut

77 perforation related to endoscopic retrograde cholangiopancreatography (ERCP), a rate of 1.0%.

78 sk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from

79 ated and compared with endoscopic retrograde cholangiopancreatography (ERCP), clinical examination, a

80 made with findings at endoscopic retrograde cholangiopancreatography (ERCP), performed within 30 day

81 common complication of endoscopic retrograde cholangiopancreatography (ERCP), resulting in substantia

82 the 2-stage approach [endoscopic retrograde cholangiopancreatography (ERCP), sphincterotomy, and com

83 copic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomogra

84 Endoscopic retrograde cholangiopancreatography (ERCP), the most commonly perfo

85 uracy when compared to endoscopic retrograde cholangiopancreatography (ERCP).

86 need for preoperative endoscopic retrograde cholangiopancreatography (ERCP).

87 scopic) have undergone endoscopic retrograde cholangiopancreatography (ERCP).

88 was pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).

89 of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).

90 of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).

91 jor complication after endoscopic retrograde cholangiopancreatography (ERCP).

92 nostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP).

93 initiating therapeutic endoscopic retrograde cholangiopancreatography (ERCP).

94 st current therapeutic endoscopic retrograde cholangiopancreatography (ERCP).

95 of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).

96 SC patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).

97 copic ultrasonography and magnetic resonance cholangiopancreatography extend the diagnostic power of

98 patients had undergone endoscopic retrograde cholangiopancreatography for attempted relief in the pas

99 patients who underwent endoscopic retrograde cholangiopancreatography for evaluation of malignancy at

100 re destined to replace endoscopic retrograde cholangiopancreatography for many diagnostic indications

101 ve patients undergoing endoscopic retrograde cholangiopancreatography for pancreatobiliary strictures

102 the latest findings on endoscopic retrograde cholangiopancreatography for the evaluation of biliary s

103 Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks).

104 Patients who had an endoscopic retrograde cholangiopancreatography had fewer recurrent biliary eve

105 duodenoscopes used for endoscopic retrograde cholangiopancreatography have highlighted the challenge

106 endoscopic ultrasound and magnetic resonance cholangiopancreatography in chronic pancreatitis diagnos

107 ) correlates well with endoscopic retrograde cholangiopancreatography in moderate to severe chronic p

108 and the performance of endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y gast

109 biliary biopsy) during endoscopic retrograde cholangiopancreatography in the absence of an alternativ

110 s the diagnostic value of magnetic resonance cholangiopancreatography in the diagnostics of biliary d

111 endoscopic ultrasound and magnetic resonance cholangiopancreatography in the evaluation of suspected

112 Patients underwent 1.5-T MR cholangiopancreatography, including DW sequences (b = 0,

113 All subjects underwent 3.0-T MR cholangiopancreatography, including serial DW imaging se

114 Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis can

115 at diclofenac prevents endoscopic retrograde cholangiopancreatography-induced pancreatitis.

116 ation recommending endoscopy (high risk), MR cholangiopancreatography (intermediate risk), or no test

117 Magnetic resonance cholangiopancreatography is a cost-effective and accurat

118 Endoscopic retrograde cholangiopancreatography is a non-surgical approach to d

119 Magnetic resonance cholangiopancreatography is a relatively noninvasive tec

120 Endoscopic retrograde cholangiopancreatography is commonly performed to remove

121 o be overlooked unless endoscopic retrograde cholangiopancreatography is performed.

122 Endoscopic retrograde cholangiopancreatography is reserved primarily for thera

123 MRI with magnetic resonance cholangiopancreatography is the preferred imaging modali

124 phy, magnetic resonance (MR) imaging, and MR cholangiopancreatography, is increasing, and many of the

125 server agreement was good for T2-weighted MR cholangiopancreatography (kappa for readers 1 and 2 = 0.

126 Advancements in the endoscopic retrograde cholangiopancreatography medical literature in the last

127 Endoscopic retrograde cholangiopancreatography mitigates this risk and should

128 esonance (MR) imaging, endoscopic retrograde cholangiopancreatography, MR cholangiopancreatography, a

129 uted tomography scanning, magnetic resonance cholangiopancreatography (MRCP) and positron emission to

130 n the study who underwent magnetic resonance cholangiopancreatography (MRCP) studies.

131 pancreatic ducts at magnetic resonance (MR) cholangiopancreatography (MRCP), because of an enlargeme

132 nts; magnetic resonance (MR) imaging with MR cholangiopancreatography (MRCP), four patients; endoscop

133 pancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP).

134 the pancreatic duct with magnetic resonance cholangiopancreatography (MRCP).

135 tic resonance imaging and magnetic resonance cholangiopancreatography (MRI/MRCP), are helpful in the

136 he effect of timing of endoscopic retrograde cholangiopancreatography on clinical outcomes, and compa

137 the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP) has been di

138 risk of developing postendoscopic retrograde cholangiopancreatography pancreatitis in high-risk peopl

139 the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.

140 experienced hands, and endoscopic retrograde cholangiopancreatography plays a diagnostic as well as t

141 MR cholangiopancreatography plays an important role in the

142 rs 1 and 3 = 0.734) and was excellent for MR cholangiopancreatography plus T1-weighted images (kappa

143 MR cholangiopancreatography alone and for MR cholangiopancreatography plus T1-weighted images were hi

144 pancreatitis following endoscopic retrograde cholangiopancreatography presents a unique opportunity f

145 EMS) may require fewer endoscopic retrograde cholangiopancreatography procedures (ERCPs) to achieve r

146 course of 40 weeks via endoscopic retrograde cholangiopancreatography procedures at a single institut

147 e biliary obstruction likely benefit from MR cholangiopancreatography rather than risk-stratified dia

148 versus noncontrast and contrast-enhanced MR cholangiopancreatography, respectively, but was also les

149 cohol), gallstones, or endoscopic retrograde cholangiopancreatography result in a cascade of events b

150 The results of endoscopic retrograde cholangiopancreatography served as the reference standar

151 underwent preoperative endoscopic retrograde cholangiopancreatography since the isolated microorganis

152 ce the introduction of endoscopic retrograde cholangiopancreatography, there have been great improvem

153 incremental cost per QALY for noncontrast MR cholangiopancreatography was $10 311.

154 Results Noncontrast MR cholangiopancreatography was most cost-effective in 45-5

155 tion cohort, timing of endoscopic retrograde cholangiopancreatography was not significantly different

156 MR cholangiopancreatography was performed in 37 consecutive

157 Initially, endoscopic retrograde cholangiopancreatography was purely a diagnostic procedu

158 MR cholangiopancreatography was successful in all patients.

159 or lipase levels, and endoscopic retrograde cholangiopancreatography was the method of diagnosis of

160 ed and/or known CP who were scheduled for MR cholangiopancreatography, were recruited and gave writte

161 gnostic utilization of endoscopic retrograde cholangiopancreatography which is now reserved primarily

162 essitating an emergent endoscopic retrograde cholangiopancreatography with biliary stenting and decom

163 our hospital where an endoscopic retrograde cholangiopancreatography with biliary stenting was perfo

164 lithiasis treated with endoscopic retrograde cholangiopancreatography with laparoscopic cholecystecto

165 a randomized trial of endoscopic retrograde cholangiopancreatography with SOM for patients with idio

166 k-stratified testing was less costly than MR cholangiopancreatography, with long-term savings of $187

167 stones, postoperative endoscopic retrograde cholangiopancreatography, wound infection, reoperation,